Topical levocabastine for the treatment of perennial allergic rhinitis.
The ultrastructure of the nasal mucosa following the use of intranasal levocabastine was studied in 20 patients suffering from perennial allergic rhinitis. The patients received twice daily 0.05 per cent levocabastine spray with a treatment duration of four weeks. At the end of the treatment period regression of the allergic process was evidenced by progressive reappearance of normal cilia and microvilli on the columnar cells, decrease of intercellular oedema and cytoplasmic vacuoles, increased number of mucous acinar cells, gradual decrease of vascular congestion, as well as diminished oedema fluid formation. The drug, however, had no effect on mast cell degranulation nor on eosinophilic infiltration. Normalization of the ultrastructural features correlated well with clinical improvement. Considering the results of the present study, levocabastine nasal spray appears to be an effective treatment for perennial allergic rhinitis and can be used with, or as an alternative to, other anti-allergic medications.
Elwany
S
S
Department of Otolaryngology-Head and Neck Surgery, Alexandria University School of Medicine, Egypt.
Bassiouny
M
M
D000281:Administration, Intranasal; D000328:Adult; D002908:Chronic Disease; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008854:Microscopy, Electron; D008855:Microscopy, Electron, Scanning; D009297:Nasal Mucosa / Q000187:drug effects* / Q000648:ultrastructure; D010880:Piperidines / Q000627:therapeutic use*; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
D006634:Histamine H1 Antagonists; D010880:Piperidines; C047340:levocabastine